Gilead acquired Arcellx to gain the development and marketing rights to anito-cel, for which GlobalData forecasts sales of ...

At the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, Florida and online from 7 to 10 December, the updated results from the multicentre, open-label, pivotal Phase II ...

Please provide your email address to receive an email when new articles are posted on . Study investigators reported limited high-grade treatment-related CRS or neurotoxicity. More than half of study ...

Cell therapy developer Arcellx contends its lead program could be a safer alternative to currently available CAR T-treatments for multiple myeloma, noting that its previously reported preliminary data ...

Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows ...

Arcellx Inc. is set to report full-year 2025 results Monday, potentially its final earnings release as an independent company ...

Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anitocabtagene autoleucel (anito-cel) which is being prepared for a filing and potential ...

Arcellx, Inc. (ACLX) is making significant progress in the development of its lead CAR-T cell therapy, anitocabtagene Autoleucel (anito-cel), for the treatment of patients with relapsed/refractory ...

Gilead Sciences, Inc.’s GILD Cell Therapy franchise currently comprises Yescarta and Tecartus. Sales from this unit decreased ...